Sami Saad1, Youssef Abdelmassih1, Rana Saad1, Damien Guindolet1, Sylvain El Khoury1, Serge Doan2, Isabelle Cochereau3, Eric E Gabison4. 1. Cornea, External Disorders and Refractive Surgery Department, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France. 2. Cornea, External Disorders and Refractive Surgery Department, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Hôpital Bichat-Claude-Bernard, Paris, France. 3. Cornea, External Disorders and Refractive Surgery Department, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Hôpital Bichat-Claude-Bernard, Paris, France; Université Paris-Diderot, Paris, France. 4. Cornea, External Disorders and Refractive Surgery Department, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Hôpital Bichat-Claude-Bernard, Paris, France; Université Paris-Diderot, Paris, France. Electronic address: egabison@for.paris.
Abstract
PURPOSE: To determine neurotrophic keratitis (NK) frequency, etiologies and prognostic factors, and evaluate the outcome of its management. METHODS: In this retrospective epidemiologic study, we reviewed the electronic records of all patients consulting our tertiary referral eye hospital between November 2009 and October 2017. NK was defined as corneal hypoesthesia or anesthesia associated with epithelial irregularities. RESULTS: Among the 305,351 patients' files screened for eligibility, 335 (354 eyes) were included, yielding an NK frequency of 11/10,000 (0.11%). Their mean ± SD age was 63.1 ± 21.0 years. Eyes were equally divided among the Mackie classification 3 stages. The most frequent etiology was herpetic eye disease (114 eyes; 32.2%). A multifactorial cause was found for 121 (34.2%) eyes. Surgery required for 118 eyes (33.3%). Respective success rates for amniotic membrane transplantation (AMT) or matrix-regeneration of stages 2 and 3, and autologous serum of stage 1 were 57.2%, 63.6% and 21.7%, with mean healing times of 15.0, 16.3 and 85 days. The overall healing rate was 79.5%, with a mean of 44.8 days to healing. Advanced initial stage, diminished corrected-distance visual acuity (CDVA) and advanced age correlated with worse final CDVA. CONCLUSIONS: NK was more frequent than previously reported in the literature. Delayed diagnoses indicated we must increase ophthalmologists' awareness of this disease for patients with decreased corneal sensitivity and abnormal epithelium. To improve prognosis and final CDVA, NK-specific treatment should be initiated as soon as the diagnosis is suspected. Patient-centered combinations of different therapeutic components and close monitoring achieved promising results.
PURPOSE: To determine neurotrophic keratitis (NK) frequency, etiologies and prognostic factors, and evaluate the outcome of its management. METHODS: In this retrospective epidemiologic study, we reviewed the electronic records of all patients consulting our tertiary referral eye hospital between November 2009 and October 2017. NK was defined as corneal hypoesthesia or anesthesia associated with epithelial irregularities. RESULTS: Among the 305,351 patients' files screened for eligibility, 335 (354 eyes) were included, yielding an NK frequency of 11/10,000 (0.11%). Their mean ± SD age was 63.1 ± 21.0 years. Eyes were equally divided among the Mackie classification 3 stages. The most frequent etiology was herpetic eye disease (114 eyes; 32.2%). A multifactorial cause was found for 121 (34.2%) eyes. Surgery required for 118 eyes (33.3%). Respective success rates for amniotic membrane transplantation (AMT) or matrix-regeneration of stages 2 and 3, and autologous serum of stage 1 were 57.2%, 63.6% and 21.7%, with mean healing times of 15.0, 16.3 and 85 days. The overall healing rate was 79.5%, with a mean of 44.8 days to healing. Advanced initial stage, diminished corrected-distance visual acuity (CDVA) and advanced age correlated with worse final CDVA. CONCLUSIONS: NK was more frequent than previously reported in the literature. Delayed diagnoses indicated we must increase ophthalmologists' awareness of this disease for patients with decreased corneal sensitivity and abnormal epithelium. To improve prognosis and final CDVA, NK-specific treatment should be initiated as soon as the diagnosis is suspected. Patient-centered combinations of different therapeutic components and close monitoring achieved promising results.
Authors: Catherine Y Liu; Andrea C Arteaga; Sammie E Fung; M Soledad Cortina; Ilya M Leyngold; Vinay K Aakalu Journal: Ocul Surf Date: 2021-02-26 Impact factor: 5.033
Authors: Alessandro Meduri; Giovanni William Oliverio; Antonio Valastro; Claudia Azzaro; Umberto Camellin; Francesco Franchina; Leandro Inferrera; Anna Roszkowska; Pasquale Aragona Journal: Front Med (Lausanne) Date: 2022-05-30
Authors: Marta Sacchetti; Chiara Komaiha; Alice Bruscolini; Giuseppe Maria Albanese; Marco Marenco; Rossella Anna Maria Colabelli Gisoldi; Augusto Pocobelli; Alessandro Lambiase Journal: Graefes Arch Clin Exp Ophthalmol Date: 2021-10-11 Impact factor: 3.117